Asthma Clinical Trials: What to Know Before You Join

If asthma symptoms keep disrupting your life despite medication, a clinical trial could offer access to treatments not yet available at your pharmacy. Here is what the process involves. More than 28 million Americans live with asthma, according to the Asthma and Allergy Foundation of America. That is roughly one in every twelve people. Among adults alone, over 23 million carry the diagnosis, and close to 40% experienced at least one attack in a recent year. Emergency departments across the country recorded nearly a million asthma-related visits, while hospital admissions numbered in the tens of thousands. These are not just statistics. They represent missed workdays, school absences, and nights spent struggling to catch a breath in the dark. Clinical trials have become a serious option for people who have cycled through standard inhalers and controller medications without finding real relief. The research landscape has shifted meaningfully in the past decade. Biologic therapies—medications that target specific immune pathways rather than broadly suppressing inflammation—now dominate the development pipeline. Tezepelumab, for example, blocks TSLP, a protein that sits upstream of the inflammatory cascade in the airways, and has demonstrated benefit across multiple asthma subtypes. A recent Phase IV real-world study called PASSAGE, conducted across the United States, deliberately included patients often left out of earlier research: Black and African American participants, adolescents, people with a history of smoking, and those with overlapping COPD. The results showed reductions in annual asthma attacks across every subgroup examined.

Understanding the Types of Trials Available

Asthma clinical trials generally fall into two buckets: interventional and observational. In an interventional study, you receive a specific treatment—maybe a new biologic injection given every few weeks, an oral medication, or a combination therapy. Some trials compare the experimental drug against a placebo, while others pit it against an existing standard treatment. Observational studies simply track your health over time without altering your medication regimen. They might involve questionnaires, lung function tests, or blood draws at scheduled intervals.

The phases matter when you are evaluating a study. Phase I trials test safety in a small group, often with healthy volunteers. Phase II starts looking at effectiveness and dosing. Phase III expands to hundreds or thousands of participants across multiple sites—hospitals, university clinics, and research centers around the country. Phase IV studies happen after a drug reaches the market, collecting real-world data on long-term outcomes and broader populations. For someone already diagnosed with asthma, Phase III and Phase IV trials are the most common entry points.

Drug companies with active respiratory programs run many of these studies. Pfizer, for instance, operates a clinical trials portal listing ongoing asthma research with detailed eligibility checklists. Academic medical centers—the University of California system, the Cleveland Clinic, Johns Hopkins, and many others—maintain their own searchable databases of local studies. The National Library of Medicine runs ClinicalTrials.gov, which remains the most comprehensive registry available to the public.

The Screening Process, Step by Step

Before you receive any study medication, there is a screening period. You will sit down with a research coordinator who walks through the informed consent document page by page. This document spells out everything: the purpose of the study, the procedures involved, how long it lasts, the potential risks and benefits, and your right to leave at any time. You can ask questions. You should ask questions. Signing the consent form simply confirms that you understand what you are getting into—it is not a binding contract.

Screening usually involves a physical exam, blood work, and lung function testing. You might undergo a methacholine challenge, a standard diagnostic test where you inhale increasing doses of a substance that triggers airway narrowing. This confirms your asthma diagnosis and measures how reactive your airways are. The research team will also review your medication history carefully. Many trials require that you have been on a stable dose of inhaled corticosteroids plus a long-acting beta-agonist for at least two months and still have uncontrolled symptoms.

Eligibility criteria vary considerably from one study to the next. Some trials recruit only people with severe eosinophilic asthma—a subtype driven by high levels of eosinophils, a specific type of white blood cell. Others seek participants with mild to moderate allergic asthma. Age requirements might start at 12, or 18, or even 6 for pediatric studies. A common thread across many trials is the requirement for documented exacerbations: at least one or two asthma attacks in the past year despite being on standard therapy. Exclusion criteria often include other lung conditions like cystic fibrosis, a significant smoking history (often defined as more than 10 or 15 pack-years), or recent use of another investigational drug.

What Participation Actually Feels Like

Consider a typical 38-week trial for an investigational biologic. You might visit the research site about ten times. Each visit could involve a blood draw, a breathing test, and an injection—either the study drug or a placebo, depending on the study design. You continue using your regular inhalers and rescue medications throughout. The research team checks in between visits, sometimes by phone or through a mobile app where you log symptoms and peak flow readings.

A participant named Maria, a 42-year-old teacher in Texas, joined a Phase III trial after years of moving between different inhaler combinations with limited success. "I was nervous about the placebo possibility," she said, "but the coordinator explained that I would still receive my usual asthma medications regardless. The extra monitoring alone gave me more insight into my triggers than I ever had before." Her experience reflects what many participants describe: the structured follow-up and frequent assessments create a clearer picture of their condition, even beyond the experimental treatment in question.

The trial team monitors you closely. If your asthma worsens, there is typically a rescue protocol in place. You can withdraw at any time for any reason, and your regular medical care continues unaffected. The relationships you build with the research staff—nurses, coordinators, physicians—often become a source of support that extends beyond the study itself.

Trial Type	Example Focus	Typical Duration	Common Participant Profile	Key Consideration
Phase III Biologic	New monoclonal antibody for severe asthma	24–52 weeks	Uncontrolled on ICS/LABA, ≥1 exacerbation per year	May involve placebo arm
Phase IV Real-World	Post-market safety and broader effectiveness	12–52 weeks	Broader inclusion, including underrepresented groups	Usually open-label, no placebo
Observational Cohort	Tracking symptoms and quality of life over time	6–24 months	Any asthma severity, stable medication regimen	No experimental treatment given
Pediatric Study	Medication safety and dosing in children	8–24 weeks	Age 6–17, mild to moderate asthma	Parental consent required
Device/Inhaler Study	New delivery mechanism or formulation	4–12 weeks	Any asthma severity, comfortable with device training	Often compares to existing inhaler

Cost, Compensation, and Practical Questions

Clinical trials do not charge participants for the study drug, study-related procedures, or study visits. Some trials also provide compensation for time and travel, though the amount varies based on study length, visit frequency, and location. A multi-visit trial requiring monthly trips to a research center typically offers more than a short observational study with one or two check-ins. You should ask about compensation during the screening call—coordinators expect the question and will give you a straightforward answer. Your regular asthma medications and any non-study medical care remain your responsibility, and your health insurance continues to cover those as it normally would.

Before committing, a conversation with the research coordinator should cover more than logistics. Ask about the study's track record: Has the drug been tested in humans before? What did earlier phases show? What happens if your asthma worsens during the trial? Who covers the cost if you need emergency care unrelated to the study? What happens when the trial ends—is there an open-label extension where all participants receive the active drug for a period afterward?

The decision to join a clinical trial is personal. It involves weighing the possibility of accessing a treatment years before it reaches the market against the uncertainty of an investigational approach. It also means contributing to research that could reshape asthma care for millions of people. The data from studies like PASSAGE and the numerous ongoing biologic trials is steadily building a more nuanced understanding of a disease that looks different in every person who has it.

If you are curious, start by searching ClinicalTrials.gov with your city and the word "asthma." Read through a few study descriptions. Notice which ones fit your profile. Then make a call. The research coordinators on the other end of the line expect hesitation and questions—that is part of their job. You are not committing to anything by asking.